Physician profile
Katie Casey
NPI 1225452501
$7,058.78
in general payments reported to CMS, 2019-2025
43 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,040 · 2022: $1,379 · 2023: $2,011 · 2024: $1,184 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,495 · Education: $85.00 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,495.31 |
| Education | $85.00 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,275.22 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $1,258.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $676.52 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $610.71 | 2021-2025 | Farxiga, Breztri |
| Medtronic, INC. | $397.46 | 2021-2024 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $317.68 | 2021-2025 | |
| Mannkind Corporation | $277.26 | 2023-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.27 | 2021-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $247.91 | 2021-2025 | |
| Beta Bionics, INC. | $167.29 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $161.13 | 2022-2025 | Repatha, Repatha, Otezla |
| Amphastar Pharmaceuticals, INC. | $108.15 | 2023-2025 | Baqsimi |
| Sanofi-Aventis U.S. LLC | $104.13 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $92.43 | 2021-2023 | |
| Corcept Therapeutics | $91.82 | 2022-2025 | Korlym |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $80.13 | 2024-2025 | Impella |
| Exact Sciences Corporation | $75.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.43 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $72.13 | 2021-2025 | Trintellix |
| Insulet Corporation | $71.13 | 2025 | Omnipod |
| Merck Sharp & Dohme LLC | $62.16 | 2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $61.73 | 2024-2025 | Rexulti |
| Nevro Corp. | $55.24 | 2022-2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $43.50 | 2022 | |
| Glaxosmithkline, LLC. | $41.48 | 2023-2024 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $32.16 | 2021 | |
| Pfizer INC. | $29.01 | 2023 | |
| Aimmune Therapeutics, INC. | $26.70 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $25.46 | 2024 | Spravato |
| Biogen, INC. | $23.94 | 2021 | |
| Sequel Med Tech, LLC | $22.45 | 2025 | Twiist |
| Phathom Pharmaceuticals, INC. | $21.95 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.43 | 2025 | Caplyta |
| Mylan Specialty L.P. | $20.78 | 2023 | Yupelri |
| Biotronik Nro, INC. | $20.69 | 2025 | Prospera |
| Hologic Sales and Service, LLC | $18.37 | 2024 | Third Wave, Thinprep 2000 Processor, Aptima |
| Sunovion Pharmaceuticals INC. | $18.25 | 2021 | |
| Boston Scientific Corporation | $17.48 | 2022 | |
| Tandem Diabetes Care, INC. | $16.42 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $15.12 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.43 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.